ROCK on, ROCK off: Amakem gets €18 million to address rho kinase side-effect problem
This article was originally published in Scrip
Executive Summary
Amakem, the Belgian ophthalmology start-up spun out from Devgen early in 2010, has secured an €18 million series A financing to take its lead drug candidate to clinical proof of concept. The firm is working on a medicinal chemistry "trick" to enable it to develop drugs which inhibit Rho Kinase (ROCK) without causing the unwanted side-effects that have tended to interfere with the development of such compounds.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.